The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) (NCT06520345)
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Who can join: Review the eligibility criteria below.
Location: Chao Family Comprehensive Cancer Centre — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- Chao Family Comprehensive Cancer Centre — Orange, California
- Biogenix Molecular LLC — Miami, Florida
- United Theranostics — Glen Burnie, Maryland
- XCancer Omaha — Omaha, Nebraska
- Columbia University Herbert Irving Comphrensive Cancer Center — New York, New York
- University Hospital — Cleveland, Ohio
- OHSU Knight Cancer Center — Portland, Oregon
- Intermountain Health — Murray, Utah
- Intermountain Health — Salt Lake City, Utah
- Westmead Hospital — Sydney, New South Wales
- Nepean Hospital — Sydney, New South Wales
- Wollongong Hospital — Wollongong, New South Wales
- Australian Prostate Centre — Melbourne, Victoria
- GenesisCare Murdoch — Perth, Western Australia
- Mater Health Services Pty Ltd — Brisbane,
- GenesisCare Maitland — East Maitland,
- Austin Health — Heidelberg,
- GensisCare Cabrini — Malvern,
- GenesisCare North Adelaide — North Adelaide,
- Royal North Shore Hospital — Saint Leonards,
- GenesisCare Tugun — Tugun,
- INITIO Medical Group — Burnaby,
- Sunnybrook Research Institute — Toronto,
- Auckland City Hospital — Grafton, Auckland
- New Zealand Clinical Research - Christchurch — Christchurch,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-resistant Prostate Cancer
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California
Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.